NASDAQ
No company description is available yet.
This page is open to everyone. A free ScanPro account adds the interactive parts, along with watchlists, paper trading with simulated money and the Academy's quizzes.
Where price sits today against its own history. A description, not a forecast.
Company figures as of Oct 15, 2026.
Average return in each calendar month, Mar 31, 2026 to Sep 30, 2026. 1 years is 1 observations a month: too few to call a pattern, so read it as history, not a calendar to trade.
As reported in the company's SEC filings. Latest: Q2 FY2026, ended Jun 30, 2026.
| Q3 FY2024Sep 30, 2024 | Q4 FY2024Dec 31, 2024 | Q1 FY2025Mar 31, 2025 | Q2 FY2025Jun 30, 2025 | Q3 FY2025Sep 30, 2025 | Q4 FY2025Dec 31, 2025 | Q1 FY2026Mar 31, 2026 | Q2 FY2026Jun 30, 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income | ||||||||
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Operating income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$1.9M |
| Net income | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$11.1M |
| EPS, diluted | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −13.66 |
| vs a year before | ···· | ···· | ···· | ···· | ···· | ···· | ···· | ···· |
| Cash flow | ||||||||
| From operations | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$539.0K |
| Capital spending | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $1.0K |
| Free cash flow | ···· | ···· | ···· | ···· | ···· | ···· | ···· | −$540.0K |
| At period end | ||||||||
| Cash | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $7.6M |
| Debt | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $215.0K |
| Shareholders' equity | ···· | ···· | ···· | ···· | ···· | ···· | ···· | $1.9M |
Free shows the latest quarter, the latest year and the last 12 months. Plus shows every period and the growth figures.See Plus
Figures are as each 10-Q and 10-K reported them, in the company's own fiscal calendar, not restated later. A company that changes how it reports a line can make one period look out of step with the rest. Growth compares the same period a year earlier and is left blank when the year before was a loss. Banks and insurers report no gross profit, so rows they don't file are left out. Every filing on SEC EDGAR
The company is actively strengthening its drug discovery subsidiary's capabilities by recruiting a leading computational chemistry expert to its advisory board, demonstrating strategic investment in expanding internal scientific capabilities and advancing its drug discovery platform.
Tone is the news provider's automated reading of each article for this stock. It describes the article, not what the price will do.
Figures describe the past, not what the price will do next. Educational tools, not investment advice.